We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info . X close

In Vitro Diagnostics Market: Growth, Size, Share, and Trends

Report Code MD 3609
Published in May, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global Forecast to 2030

Overview

The global in vitro diagnostics market is projected to reach USD 157,632.5 million by 2030 from USD 109,065.5 million in 2025, at a CAGR of 7.6% during the forecast period. The rising incidence of chronic diseases such as diabetes, cardiovascular conditions, and cancer is triggering enhanced demand for precise and timely diagnostic testing. Emerging technologies in fields such as molecular diagnostics, next-generation sequencing (NGS), and liquid biopsy are enhancing the accuracy and pace of these tests, which is contributing to the shift of healthcare toward more targeted treatments. There is also a rising demand for quick, portable testing solutions, especially in urgent care situations, remote areas, and at home. Another major factor is the growing number of older adults, especially in places like Europe, Japan, and the US, who need ongoing monitoring due to their higher risk of both chronic and infectious diseases. Government-led healthcare reforms and investments in diagnostic infrastructure in emerging markets such as Asia Pacific, Latin America, and Africa are making testing more accessible and expanding the reach of the IVD market.

In Vitro Diagnostics Market

Attractive Opportunities in the In Vitro Diagnostics Market

Asia Pacific

The high growth rate of the Asia Pacific is attributed to the rising prevalence of chronic and infectious diseases across China, India, and Southeast Asian countries, as well as increased healthcare spending and improved access to diagnostic services, particularly in emerging economies.

The growth of the in vitro diagnostics market is attributed to the emergence of rapid PoC technologies and rising adoption of automated analyzers

Emerging markets are expected to offer significant growth opportunities for players operating in the in vitro diagnostics market.

The Asia Pacific market is projected to hold the highest CAGR in the in vitro diagnostic market during the forecast period.

The high cost of diagnostic equipment is expected to restrain the market growth to a certain extent.

Global In Vitro Diagnostics Market Dynamics

DRIVER: Growing awareness of early disease diagnosis in emerging economies

There is increasing awareness of the need for early disease detection, particularly among developing economies. As the urbanization grows in emerging economies, the need for enhanced healthcare access and outcomes becomes more and more imperative. This is increasing the awareness among consumers and healthcare practitioners regarding the necessity of early detection of diseases—specifically diabetes, cancer, and cardiovascular diseases. In the IDF Diabetes Atlas 2025, approximately 11.1% of global adults aged 20-79 years old have diabetes, and over 40% are unaware of it. This change is backed by government efforts toward improving public health, as well as more healthcare infrastructure and diagnostic facility investments.

RESTRAINT: Stringent regulatory requirements

Regulations are complex and can cause product development, approval, and release delays. In the European Union, the US, and Japan, IVD manufacturers have to adhere to stringent regulatory requirements from agencies such as the Food and Drug Administration (FDA), Conformité Européenne (CE), and Pharmaceuticals and Medical Devices Agency (PMDA). The demand for wide clinical trials, paperwork, and following quality assurance systems can hike prices and push timelines to the market. Secondarily, the constantly changing character of regulatory paradigms, for example, recent modifications of the EU’s In Vitro Diagnostic Regulation (IVDR), contributes to the uncertainty and added complexity for the manufacturer.

 

OPPORTUNITY: Improvements in immunoassay diagnostic technologies

New technologies in immunoassay are speeding up diagnostic tests, making them more accurate and sensitive. Techniques such as chemiluminescence and fluorescence immunoassays enable faster and more consistent detection of diseases such as infections, cancer, and cardiovascular disorders. Such advancements enable the identification of biomarkers at low levels with higher accuracy, paving the way for earlier diagnoses and targeted treatments that can produce improved outcomes. Additionally, the increasing usage of point-of-care testing is driving demand for rapid and convenient immunoassays. They provide instant results at the patient care location and are especially beneficial in emergency care or in the field where there may be less access to central laboratory facilities.

CHALLENGES: Data privacy and cybersecurity risks

As more healthcare systems incorporate digital technologies—such as cloud storage for patient data, mobile applications for tracking, and networked diagnostic equipment—the threat of cyberattacks and data breaches is growing. These systems typically manage sensitive data, including genetic information and test results, and are thus attractive targets for cyberhackers. According to Scrut Automation (US), in 2024, 720 healthcare data breaches were reported in US healthcare, impacting around 186 million patient records. The trend is due to the sensitive information nature of patient data, the health IT infrastructure complexity, and the growing prevalence of ransomware attacks on healthcare organizations and hospitals.

Global In Vitro Diagnostics Market Ecosystem Analysis

The ecosystem market map of the IVD market includes products and services used in the field, types of testing, technologies used, indications, application areas, and end users. Manufacturers of various diagnostic products include organizations involved in research, product development, optimization, and launch. Distributors include third parties and e-commerce sites linked with the organization to market IVD products. Research and product development include in-house research facilities, contract research organizations, and contract development & manufacturing organizations that play a key role in outsourcing services for product development to manufacturers. End users adopt IVD products and services during various stages of diagnosis. These end customers are the key stakeholders in the supply chain of the IVD market.

In Vitro Diagnostics Market
 

By site of testing, the point-of-care tests segment commanded the highest CAGR in 2024.

Based on site of testing, the in vitro diagnostics market is divided into laboratory tests and point-of-care tests. The point-of-care tests segment holds the highest CAGR in 2024. As healthcare systems work to cut costs and improve efficiency, point-of-care (POC) testing is becoming a more affordable alternative to traditional lab tests. It helps save time and resources by eliminating the need to transport and process samples in a lab. With a growing emphasis on personalized and preventive care, POC testing enables real-time disease monitoring, allowing for more customized treatment plans and better management of chronic conditions. Thanks to continuous advancements in diagnostic technology, such as portable devices and easy-to-use test kits, POC testing is becoming more reliable and accessible for doctors and patients.

By end user, the hospitals & clinics segment held the largest market share in 2024.

Based on end users, the in vitro diagnostics market has been classified into hospitals & clinical laboratories, blood banks, home care, pharmaceutical and biotechnology companies, academic institutes, and other end users. Hospitals & clinics hold the largest market share. Hospitals and clinics are using more advanced diagnostic tools these days, such as molecular diagnostics, immunoassays, and next-generation sequencing, to make tests faster, more accurate, and more reliable. At the same time, many countries are boosting healthcare funding and updating reimbursement policies, making it easier and more affordable for hospitals and clinics to offer these tests.

By region, the Asia Pacific is expected to showcase the highest CAGR during the forecast period.

Asia Pacific is the fastest-growing regional market for in vitro diagnostics, driven by considerable growth in key nations, including China, Japan, and India. The region is home to several renowned players, including Sysmex Corporation (Japan), J. Mitra & Co. Pvt. Ltd. (India), Luye Life Sciences Group (China), and SpeeDx Pty. Ltd. (Australia). As these players are continuously investing in R&D and launching new in vitro diagnostics products and services globally, the market is continuously increasing. Additionally, the rising aging population has increased the demand for in vitro diagnostics. As people age, they are more prone to chronic and age-related conditions such as cardiovascular diseases, diabetes, cancer, and neurodegenerative disorders. These conditions require early detection, regular monitoring, and personalized treatment, all of which depend heavily on IVD tests (e.g., blood tests, urinalysis, genetic testing).

CHINA: LARGEST MARKET SHARE IN ASIA PACIFIC IN 2024
ASIA PACIFIC: FASTEST-GROWING MARKET IN REGION
In Vitro Diagnostics Market

Recent Developments of In Vitro Diagnostics Market

  • Product Launch: In February of 2025, F. Hoffmann-La Roche Ltd (Switzerland) launched a novel class of next-generation sequencing (NGS) powered by Sequencing by Expansion (SBX). This new-generation technology is designed to make sequencing faster, more precise, and more scalable.
  • Product Approval: Beckman Coulter Diagnostics (US) (a Danaher company) received FDA approval for its DxC 500i Clinical Analyzer in March of 2025. It performs clinical chemistry and immunoassay tests, enabling labs to become more efficient and streamlined.
  • Partnership: In May 2024, MeMed Ltd. (Israel) partnered with Beckman Coulter to distribute the MeMed's BV test, a fast and accurate immunoassay, as well as the MeMed Key analyzer. They are approved in the US and European Union.
  • Acquisition: In November 2024, F. Hoffmann-La Roche Ltd (Switzerland) acquired Poseida Therapeutics, Inc. (US), a biotech firm famous for its research on donor-derived CAR-T cell therapies. The acquisition aids Roche in expanding its franchise in the advanced field of cell and gene therapy.

Key Market Players

KEY PLAYERS IN THE IN VITRO DIAGNOSTICS MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in In Vitro Diagnostics Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD Million/Billion)
Segments covered Product & Service, Technology, Specimen, Site of Testing, Application, End User, and Region
Geographies covered North America (US & Canada), Europe (Germany, France, UK, Italy, Spain, Russia, Switzerland, and RoE), APAC (China, Japan, India, Australia, South Korea, Singapore, and the RoAPAC), Latin America (Brazil, Mexico, and RoLATAM), Middle East & Africa, and GCC Countries (Saudi Arabia, UAE, and Other GCC Countries).

Frequently Asked Questions (FAQ)

Which are the top industry players in the global in vitro diagnostics market?

Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers (Germany), Thermo Fisher Scientific (US), Illumina (US), Hologic (US), Bio-Rad (US), bioMérieux (France), Sysmex (Japan), and others.

What are some of the major drivers for this market?

Increasing geriatric population and chronic diseases, rising awareness of early diagnosis in emerging markets, rapid PoC technologies, adoption of automated analyzers, and growing demand for personalized medicine.

Which end users have been included in the global in vitro diagnostics market?

 

  • Hospitals & Clinics
  • Clinical Laboratories
  • Blood Banks
  • Home Care
  • Pharmaceutical & Biotechnology Companies
  • Academic Institutes
  • Other End Users

 

Which type of in vitro diagnostics product is lucrative for the market?

The reagents & kits segment is expected to witness the highest growth rate during the forecast period.

Which region is lucrative for the in vitro diagnostics market?

The Asia Pacific region is expected to witness the highest CAGR during the forecast period.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the In Vitro Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
57
RESEARCH METHODOLOGY
62
EXECUTIVE SUMMARY
75
PREMIUM INSIGHTS
82
MARKET OVERVIEW
86
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing geriatric population and subsequent rise in chronic diseases
    - Growing awareness of early disease diagnosis in emerging economies
    - Emergence of rapid PoC technologies and rising adoption of automated analyzers
    - Growing preference for personalized medicines
    RESTRAINTS
    - Unfavorable reimbursement scenario
    - Stringent regulatory requirements
    - High cost of diagnostic equipment
    OPPORTUNITIES
    - Introduction of disease-specific biomarkers and tests
    - Increasing significance of companion diagnostics
    - Growth opportunities in developing countries
    - Improvements in immunoassay diagnostic technologies
    - Digitalization trend
    CHALLENGES
    - Operational barriers
    - Data privacy and cybersecurity risks
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND, BY KEY PLAYER
    AVERAGE SELLING PRICE TREND, BY REGION
    AVERAGE SELLING PRICE TREND, BY PRODUCT
  • 5.5 VALUE CHAIN ANALYSIS
    RESEARCH & DEVELOPMENT
    RAW MATERIAL SUPPLIERS
    MANUFACTURING
    DISTRIBUTION, MARKETING, AND SALES
    RETAILERS
    POST-SALES SERVICES
  • 5.6 SUPPLY CHAIN ANALYSIS
    PROMINENT COMPANIES
    SMALL & MEDIUM-SIZED ENTERPRISES
    END USERS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    COMPLEMENTARY TECHNOLOGIES
    - Immunohistochemistry
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
    IMPORT DATA FOR HS CODE 382200
    EXPORT DATA FOR HS CODE 382200
  • 5.12 KEY CONFERENCES AND EVENTS, 2025–2026
  • 5.13 CASE STUDY ANALYSIS
    CASE STUDY 1: LOCALIZED STRATEGY TO TAP MARKET POTENTIAL IN EUROPE
    CASE STUDY 2: ENHANCED COMPANY FOOTPRINT IN COMPETITIVE INDIAN MARKET
    CASE STUDY 3: CUSTOMER-CENTRIC DIFFERENTIATION FOR PRODUCT OPTIMIZATION AND PREMIUM PRICING
  • 5.14 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.15 REGULATORY FRAMEWORK
    NORTH AMERICA
    - US
    - Canada
    EUROPE
    ASIA PACIFIC
    - Japan
    - China
    - India
    - South Korea
    - Indonesia
    - Russia
    MIDDLE EAST & AFRICA
    - Saudi Arabia
    - Africa
    LATIN AMERICA
    - Mexico
    - Brazil
  • 5.16 PORTER’S FIVE FORCES ANALYSIS
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.18 RECENT POLICY CHANGES IN US MARKET AND THEIR POTENTIAL IMPACT ON APPROVAL PROCESS
  • 5.19 INFLUENCE OF TARIFFS ON SUPPLY CHAIN RESILIENCE OF MEDTECH COMPANIES
  • 5.20 GROWTH OF DECENTRALIZED TESTING VS. ADOPTION OF COST-EFFECTIVE CENTRALIZED TESTING
  • 5.21 IMPACT OF AI/GENERATIVE AI ON IN VITRO DIAGNOSTICS MARKET
    INTRODUCTION
    MARKET POTENTIAL OF AI IN IVD DEVICES
    AI USE CASES
    KEY COMPANIES IMPLEMENTING AI
    FUTURE OF GENERATIVE AI IN IN VITRO DIAGNOSTICS MARKET
IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
141
  • 6.1 INTRODUCTION
  • 6.2 REAGENTS & KITS
    RISE IN TEST VOLUMES ACROSS CLINICAL LABS, HOSPITALS, AND POINT-OF-CARE SETTINGS TO AID GROWTH
  • 6.3 INSTRUMENTS
    GROWING TREND OF AUTOMATION TO DRIVE MARKET
  • 6.4 DATA MANAGEMENT SOFTWARE & SERVICES
    INCREASING SHIFT TOWARD CLOUD-BASED PLATFORMS AND REMOTE DATA ACCESS TO STIMULATE GROWTH
IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY
156
  • 7.1 INTRODUCTION
  • 7.2 IMMUNOASSAYS
    ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
    - Increasing use of immunoassays in cancer, infectious disease testing, and therapeutic drug monitoring to aid growth
    CHEMILUMINESCENCE IMMUNOASSAYS
    - Need for minimal human intervention to support growth
    IMMUNOFLUORESCENCE ASSAYS
    - Growing introduction of innovative diagnostic platforms to drive market
    RAPID TESTS
    - Need for rapid diagnostic tests to expedite growth
    ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)
    - Need for early detection and monitoring of immune-related disorders to amplify growth
    WESTERN BLOTTING
    - Increasing focus on biomarker discovery and personalized treatment to advance growth
    OTHER IMMUNOASSAY TECHNOLOGIES
  • 7.3 CLINICAL CHEMISTRY
    BASIC METABOLIC PANELS
    - Increasing incidence of diabetes, kidney disorders, and hypertension to promote growth
    LIVER PANELS
    - Rising prevalence of cirrhosis and viral hepatitis to foster growth
    RENAL PROFILES
    - Growing awareness for preventive health check-ups to boost market
    LIPID PROFILES
    - Rising prevalence of obesity to accelerate growth
    THYROID FUNCTION PROFILES
    - High incidence of thyroid-related disorders to support growth
    ELECTROLYTE PANELS
    - Growing shift toward home care and remote patient monitoring to fuel market
    SPECIALTY CHEMICAL TESTS
    - Rising demand for specialized tests to contribute to growth
  • 7.4 MOLECULAR DIAGNOSTICS
    POLYMERASE CHAIN REACTION
    - High accuracy and speed in detecting pathogens to aid growth
    ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    - Growing focus on rapid, onsite molecular diagnostics to propel market
    DNA SEQUENCING & NEXT-GENERATION SEQUENCING
    - Growing applications in research, drug discovery, and molecular diagnostics to boost market
    IN SITU HYBRIDIZATION
    - Rising prevalence of cancer and genetic disorders to assist growth
    DNA MICROARRAYS
    - High resolution and throughput capabilities to favor growth
    OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
  • 7.5 GLUCOSE MONITORING
    ONGOING TECHNOLOGICAL ADVANCEMENTS IN BLOOD GLUCOSE SELF-MONITORING DEVICES TO AID GROWTH
  • 7.6 HEMATOLOGY
    GROWING FOCUS ON STEM CELL RESEARCH TO BOOST MARKET
  • 7.7 MICROBIOLOGY
    RISING PREVALENCE OF MICROBIAL INFECTIONS TO SUSTAIN GROWTH
  • 7.8 COAGULATION & HEMOSTASIS
    GROWING CASES OF PULMONARY EMBOLISM, HEMOPHILIA, LIVER DISEASES TO DRIVE MARKET
  • 7.9 BLOOD GAS ANALYZERS
    GROWING SURGICAL INTERVENTIONS AND RISE IN ELDERLY POPULATION TO FUEL MARKET
  • 7.10 URINALYSIS
    RISING INCIDENCE OF URINARY TRACT INFECTIONS TO SUPPORT GROWTH
  • 7.11 CHROMATOGRAPHY & MASS SPECTROMETRY
    INCREASING APPLICATIONS IN DISEASE SCREENING AND DIAGNOSTICS TO AID GROWTH
IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN
270
  • 8.1 INTRODUCTION
  • 8.2 BLOOD, SERUM, AND PLASMA SPECIMENS
    GROWING SHIFT TOWARD DECENTRALIZED TESTING TO PROPEL MARKET
  • 8.3 SALIVA SPECIMENS
    GROWING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS TO BOOST MARKET
  • 8.4 URINE SPECIMENS
    RISING INCIDENCE OF URINARY TRACT INFECTIONS TO ACCELERATE GROWTH
  • 8.5 OTHER SPECIMENS
IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING
286
  • 9.1 INTRODUCTION
  • 9.2 LABORATORY TESTS
    INCREASING FOCUS ON EARLY AND ACCURATE DISEASE DETECTION TO ENCOURAGE GROWTH
  • 9.3 POINT-OF-CARE TESTS
    RISING DEMAND FOR DECENTRALIZED HEALTHCARE TO CONTRIBUTE TO GROWTH
IN VITRO DIAGNOSTICS MARKET, BY APPLICATION
299
  • 10.1 INTRODUCTION
  • 10.2 INFECTIOUS DISEASES
    INCREASING PREVALENCE OF VIRAL, BACTERIAL, AND PARASITIC INFECTIONS TO PROMOTE GROWTH
  • 10.3 ONCOLOGY
    RISING GLOBAL BURDEN OF CANCER TO EXPEDITE GROWTH
  • 10.4 ENDOCRINOLOGY
    INCREASING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO BOLSTER GROWTH
  • 10.5 CARDIOLOGY
    GROWING USE OF IMMUNOASSAYS IN CARDIOVASCULAR DISEASE DETECTION TO DRIVE MARKET
  • 10.6 BLOOD SCREENING
    RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT GROWTH
  • 10.7 GENETIC TESTING
    INCREASING CLINICAL UTILITY OF GENETIC TESTS ACROSS ONCOLOGY, RARE DISEASES, AND REPRODUCTIVE HEALTH TO FOSTER GROWTH
  • 10.8 AUTOIMMUNE DISEASES
    RISE IN AUTOIMMUNE CONDITIONS GLOBALLY TO FACILITATE GROWTH
  • 10.9 ALLERGY DIAGNOSTICS
    INCREASING AWARENESS ABOUT ALLERGIES TO AMPLIFY GROWTH
  • 10.10 DRUG MONITORING & TESTING
    INCREASING ILLICIT DRUG CONSUMPTION TO SUSTAIN GROWTH
  • 10.11 BONE & MINERAL DISORDERS
    RISING CASES OF OSTEOPOROSIS TO FUEL MARKET
  • 10.12 COAGULATION TESTING
    INCREASING PREVALENCE OF HEMOPHILIA TO ADVANCE GROWTH
  • 10.13 BLOOD GROUP TYPING
    RISING NUMBER OF SURGICAL PROCEDURES TO SPEED UP GROWTH
  • 10.14 OTHER APPLICATIONS
IN VITRO DIAGNOSTICS MARKET, BY END USER
349
  • 11.1 INTRODUCTION
  • 11.2 HOSPITALS & CLINICS
    EXPANDING HEALTHCARE INFRASTRUCTURE TO SPEED UP GROWTH
  • 11.3 CLINICAL LABORATORIES
    LARGE REFERENCE LABORATORIES
    - Growing test volume and complexity of diagnostic testing to propel market
    SMALL AND MEDIUM-SIZED LABORATORIES
    - Increasing shift toward community-based and point-of-care settings to foster growth
  • 11.4 BLOOD BANKS
    NEED TO ADDRESS PUBLIC HEALTH AND SAFETY CHALLENGES TO AID GROWTH
  • 11.5 HOME CARE SETTINGS
    GROWING INCLINATION TOWARD SELF-DIAGNOSIS AND MONITORING TO BOOST MARKET
  • 11.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    INCREASING USE OF IVD PRODUCTS IN CLINICAL DRUG DEVELOPMENT AND COMPANION DIAGNOSTICS TO DRIVE MARKET
  • 11.7 ACADEMIC INSTITUTES
    RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO AUGMENT GROWTH
  • 11.8 OTHER END USERS
IN VITRO DIAGNOSTICS MARKET, BY REGION
382
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Established reimbursement framework and favorable policies for IVD providers to drive market
    CANADA
    - Favorable funding initiatives for early disease diagnosis to fuel market
  • 12.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Increasing investments in clinical diagnostics research to aid growth
    FRANCE
    - High healthcare expenditure and rising investments in genomic medicine to drive market
    UK
    - Rising adoption of genome-based testing to encourage growth
    ITALY
    - Growing geriatric population and subsequent rise in chronic conditions to boost market
    SPAIN
    - Increasing adoption of technologically advanced immunoassay systems to expedite growth
    RUSSIA
    - High incidence of respiratory infectious diseases to boost market
    SWITZERLAND
    - Growing prevalence of chronic diseases to propel market
    REST OF EUROPE
  • 12.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    JAPAN
    - Increasing research investments for immunoassays to encourage growth
    CHINA
    - Growing focus on preventive care to boost market
    INDIA
    - Rising incidence of diabetes and cancer to augment growth
    SOUTH KOREA
    - Rising healthcare spending for innovative IVD technologies to amplify growth
    AUSTRALIA
    - Increasing incidence of chronic diseases and rising blood donations to fuel market
    SINGAPORE
    - Rising technological advancements and automation to stimulate growth
    REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Rising prevalence of diabetes to sustain growth
    MEXICO
    - Growing establishment of clinical laboratories to fuel market
    REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    GROWING FOCUS ON PRENATAL AND CANCER TESTING TO DRIVE MARKET
    MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 12.7 GCC COUNTRIES
    GCC COUNTRIES: MACROECONOMIC OUTLOOK
    SAUDI ARABIA
    - Rising government healthcare expenditure to boost market
    UAE
    - Improvements in healthcare infrastructure to support growth
    OTHER GCC COUNTRIES
COMPETITIVE LANDSCAPE
561
  • 13.1 OVERVIEW
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 13.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • 13.4 REVENUE ANALYSIS, 2022–2024
  • 13.5 MARKET SHARE ANALYSIS, 2024
  • 13.6 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.7 BRAND/PRODUCT COMPARISON
  • 13.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Product & service footprint
    - Technology footprint
    - End-user footprint
  • 13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs
  • 13.10 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES AND APPROVALS
    DEALS
    EXPANSIONS
  • 13.11 POTENTIAL FUTURISTIC STRATEGIES OF LEADING PLAYERS OPERATING IN IVD MARKET
    PRODUCT LAUNCHES AND APPROVALS
    DEALS
COMPANY PROFILES
585
  • 14.1 KEY PLAYERS
    DANAHER
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    ABBOTT
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    SIEMENS HEALTHINEERS AG
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    ILLUMINA, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    HOLOGIC, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    BIO-RAD LABORATORIES, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    BIOMÉRIEUX
    - Business overview
    - Products/Services offered
    - Recent developments
    SYSMEX CORPORATION
    - Business overview
    - Products/Services offered
    - Recent developments
    REVVITY
    - Business overview
    - Products/Services offered
    - Recent developments
    BECTON, DICKINSON AND COMPANY
    - Business overview
    - Products/Services offered
    - Recent developments
    AGILENT TECHNOLOGIES, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    QIAGEN
    - Business overview
    - Products/Services offered
    - Recent developments
    DIASORIN S.P.A.
    - Business overview
    - Products/Services offered
    - Recent developments
    GRIFOLS, S.A.
    - Business overview
    - Products/Services offered
    - Recent developments
    WERFEN
    - Business overview
    - Products/Services offered
    QUIDELORTHO CORPORATION
    - Business overview
    - Products/Services offered
    - Recent developments
  • 14.2 OTHER PLAYERS
    DEVYSER
    BIOSYNEX SA
    SURMODICS, INC.
    MENARINI SILICON BIOSYSTEMS
    SPEEDX PTY. LTD.
    GENSPEED BIOTECH GMBH
    MERCK KGAA
    CARIS LIFE SCIENCES
    ARKRAY, INC.
    ACCELERATE DIAGNOSTICS, INC.
    CELLABS
    J. MITRA & CO. PVT. LTD.
    EPITOPE DIAGNOSTICS, INC.
    BOSTER BIOLOGICAL TECHNOLOGY
    ENZO BIOCHEM INC.
    GENETIC SIGNATURES
    SAVYON DIAGNOSTICS
    TRIVITRON HEALTHCARE
    MDXHEALTH
    CREATIVE DIAGNOSTICS
    INBIOS INTERNATIONAL, INC.
    MACCURA BIOTECHNOLOGY CO., LTD.
    LUYE LIFE SCIENCES GROUP
APPENDIX
728
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 IN VITRO DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IN VITRO DIAGNOSTICS MARKET: RISK ASSESSMENT
  • TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION, 2022−2050
  • TABLE 4 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES, 2022−2024
  • TABLE 5 APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE
  • TABLE 6 RECENT DEVELOPMENTS IN IVD MARKET, 2021–2023
  • TABLE 7 AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)
  • TABLE 8 AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2022–2024 (USD)
  • TABLE 9 AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY TYPE, 2022–2024 (USD)
  • TABLE 10 IN VITRO DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 11 IN VITRO DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022−2024
  • TABLE 12 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION)
  • TABLE 13 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION)
  • TABLE 14 IN VITRO DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025−2026
  • TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 US: CLASSIFICATION OF IVD DEVICES
  • TABLE 21 EUROPE: CLASSIFICATION OF IVD DEVICES
  • TABLE 22 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
  • TABLE 23 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 24 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 25 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 26 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
  • TABLE 27 RUSSIA: CLASSIFICATION OF IVD DEVICES
  • TABLE 28 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 29 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 30 IN VITRO DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS (%)
  • TABLE 32 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • TABLE 33 US: OVERVIEW OF CERTAIN KEY CATEGORIES OF IVD DEVICES
  • TABLE 34 TARIFF RATES IMPOSED BY US, AS OF APRIL 2025
  • TABLE 35 COMPARATIVE ANALYSIS OF CENTRALIZED VS. DECENTRALIZED TESTING
  • TABLE 36 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 37 IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 38 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 39 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 41 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 42 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 43 KEY IVD INSTRUMENTS AVAILABLE WORLDWIDE
  • TABLE 44 IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 45 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 46 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 48 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 49 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 50 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE WORLDWIDE
  • TABLE 51 IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 52 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 53 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 54 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 55 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 56 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 57 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 58 KEY IMMUNOASSAY ANALYZERS AVAILABLE WORLDWIDE
  • TABLE 59 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 60 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 61 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 62 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 64 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 65 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 66 KEY ELISA ANALYZERS AVAILABLE WORLDWIDE
  • TABLE 67 IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 68 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 69 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 70 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 71 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 72 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 73 KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE WORLDWIDE
  • TABLE 74 IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 75 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 76 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 78 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 79 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 80 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 81 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 82 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 83 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 84 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 85 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 86 KEY RAPID TESTS AVAILABLE WORLDWIDE
  • TABLE 87 IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 88 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 89 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 90 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 91 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 92 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 93 IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 94 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 95 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 97 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 98 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 99 KEY WESTERN BLOTTING SYSTEMS AVAILABLE WORLDWIDE
  • TABLE 100 IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 101 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 102 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 104 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 105 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 106 IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 107 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 108 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 110 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 111 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 112 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES AVAILABLE WORLDWIDE
  • TABLE 113 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES AVAILABLE WORLDWIDE
  • TABLE 114 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 115 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 116 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 117 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 119 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 120 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 121 IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 122 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 123 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 125 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 126 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 127 IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 128 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 129 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 131 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 132 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 133 IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 134 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 135 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 137 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 138 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 139 IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 140 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 141 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 142 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 143 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 144 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 145 IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 146 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 147 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 148 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 149 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 150 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 151 REFERENCE RANGES AND ABNORMAL CONDITIONS FOR KEY ELECTROLYTES
  • TABLE 152 IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 153 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 154 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 156 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 157 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS,BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 158 IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 159 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 160 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 162 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 163 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 164 KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE WORLDWIDE
  • TABLE 165 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 166 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 167 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 168 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 169 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 170 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 171 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 172 KEY POLYMERASE CHAIN REACTION INSTRUMENTS AVAILABLE WORLDWIDE
  • TABLE 173 IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 174 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 175 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 176 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 177 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 178 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 179 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INSTRUMENTS AVAILABLE WORLDWIDE
  • TABLE 180 IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 181 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 182 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 184 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 185 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 186 KEY NEXT-GENERATION SEQUENCING-BASED INSTRUMENTS AVAILABLE WORLDWIDE
  • TABLE 187 IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 188 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 189 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 190 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 191 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 192 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 193 IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 194 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 195 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 196 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 197 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 198 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 199 IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 200 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 201 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 203 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 204 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 205 IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 206 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 207 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 209 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 210 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 211 DIABETES-RELATED HEALTH EXPENDITURE PER PERSON, 2021 VS. 2030 VS. 2045 (USD)
  • TABLE 212 IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 213 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 214 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 216 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 217 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 218 IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 219 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 220 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 221 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 222 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 223 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 224 IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 225 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 226 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 228 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 229 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 230 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 231 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 232 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 234 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 235 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 236 KEY BLOOD GAS ANALYZERS AVAILABLE WORLDWIDE
  • TABLE 237 IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 238 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 239 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 240 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 241 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 242 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZER, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 243 IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 244 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 245 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 246 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 247 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 248 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 249 IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 250 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 251 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 252 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 253 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 254 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 255 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 256 KEY BLOOD, SERUM, AND PLASMA SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 257 IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 258 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 259 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 260 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 261 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 262 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 263 IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 264 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 265 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 266 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 267 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 268 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 269 KEY URINE SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 270 IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 271 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 272 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 273 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 274 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 275 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 276 IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 277 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 278 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 279 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 280 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 281 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 282 IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING, 2022–2030 (USD MILLION)
  • TABLE 283 IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 284 IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 285 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 286 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 287 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 288 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 289 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 290 IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 291 IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 292 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 293 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 294 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 295 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 296 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 297 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 298 IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 299 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 300 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 301 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 302 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 303 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 304 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2040
  • TABLE 305 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES, 2022–2024
  • TABLE 306 IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 307 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 308 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY,2022–2030 (USD MILLION)
  • TABLE 309 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 310 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 311 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 312 IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 313 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 314 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 315 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 316 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 317 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 318 IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 319 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 320 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 321 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 322 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 323 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 324 IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 325 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 326 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 327 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 328 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 329 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 330 IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 331 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 332 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 333 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 334 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 335 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 336 IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 337 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 338 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 339 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 340 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 341 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 342 IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 343 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 344 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 345 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 346 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 347 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 348 KEY PRODUCTS FOR DRUG MONITORING WORLDWIDE
  • TABLE 349 KEY IVD PRODUCTS FOR DRUG TESTING WORLDWIDE
  • TABLE 350 IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 351 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 352 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 353 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 354 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 355 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 356 KEY PRODUCTS FOR BONE & MINERAL DISORDERS WORLDWIDE
  • TABLE 357 IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 358 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 359 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 360 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 361 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 362 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 363 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 364 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 365 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 366 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 367 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 368 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 369 IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 370 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 371 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 372 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 373 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 374 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 375 IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 376 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 377 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 378 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 379 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 380 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 381 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 382 IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 383 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 384 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 385 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 386 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 387 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 388 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 389 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 390 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 391 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 392 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 393 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 394 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 395 IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 396 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 397 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 398 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 399 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 400 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 401 IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 402 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 403 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 404 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 405 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 406 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 407 IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 408 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 409 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 410 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 411 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 412 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 413 IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 414 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 415 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 416 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 417 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 418 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 419 IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 420 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 421 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 422 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 423 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 424 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 425 IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 426 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 427 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 428 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 429 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 430 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 431 IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 432 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 433 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 434 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 435 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 436 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 437 IN VITRO DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 438 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 439 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 440 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 441 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 442 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 443 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 444 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 445 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 446 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 447 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 448 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 449 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 450 US: KEY MACROECONOMIC INDICATORS
  • TABLE 451 US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED, 2022–2030 (BILLION)
  • TABLE 452 US: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 453 US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 454 US: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 455 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 456 US: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 457 US: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 458 US: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 459 US: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 460 US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 461 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 462 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034
  • TABLE 463 CANADA: KEY MACROECONOMIC INDICATORS
  • TABLE 464 CANADA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 465 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 466 CANADA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 467 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 468 CANADA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 469 CANADA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 470 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 471 CANADA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 472 CANADA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 473 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 474 EUROPE: KEY MACROECONOMIC INDICATORS
  • TABLE 475 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 476 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 477 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 478 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 479 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 480 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 481 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 482 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 483 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 484 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 485 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 486 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 487 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 488 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 489 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 490 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 491 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 492 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 493 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 494 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 495 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 496 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 497 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 498 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 499 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 500 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 501 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 502 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 503 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 504 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 505 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 506 UK: KEY MACROECONOMIC INDICATORS
  • TABLE 507 UK: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 508 UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 509 UK: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 510 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 511 UK: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 512 UK: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 513 UK: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 514 UK: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 515 UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 516 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 517 ITALY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 518 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 519 ITALY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 520 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 521 ITALY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 522 ITALY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 523 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 524 ITALY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 525 ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 526 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 527 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 528 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 529 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 530 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 531 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 532 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 533 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 534 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 535 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 536 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 537 RUSSIA: KEY MACROECONOMIC INDICATORS
  • TABLE 538 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 539 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 540 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 541 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 542 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 543 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 544 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 545 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 546 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 547 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 548 SWITZERLAND: KEY MACROECONOMIC INDICATORS
  • TABLE 549 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 550 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 551 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 552 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 553 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 554 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 555 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 556 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 557 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 558 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 559 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 560 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 561 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 562 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 563 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 564 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 565 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 566 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 567 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 568 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 569 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
  • TABLE 570 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 571 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 572 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 573 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 574 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 575 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 576 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 577 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 578 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 579 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 580 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 581 JAPAN: KEY MACROECONOMIC INDICATORS
  • TABLE 582 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 583 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 584 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 585 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 586 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 587 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 588 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 589 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 590 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 591 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 592 CHINA: KEY MACROECONOMIC INDICATORS
  • TABLE 593 CHINA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 594 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 595 CHINA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 596 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 597 CHINA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 598 CHINA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 599 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 600 CHINA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 601 CHINA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 602 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 603 INDIA: KEY MACROECONOMIC INDICATORS
  • TABLE 604 INDIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 605 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 606 INDIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 607 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 608 INDIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 609 INDIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 610 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 611 INDIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 612 INDIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 613 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 614 SOUTH KOREA: KEY MACROECONOMIC INDICATORS
  • TABLE 615 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 616 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 617 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 618 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 619 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 620 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 621 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 622 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 623 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 624 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 625 AUSTRALIA: KEY MACROECONOMIC INDICATORS
  • TABLE 626 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 627 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 628 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 629 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 630 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 631 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 632 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 633 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 634 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 635 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 636 SINGAPORE: KEY MACROECONOMIC INDICATORS
  • TABLE 637 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 638 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 639 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 640 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 641 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 642 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 643 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 644 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 645 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 646 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 647 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 648 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 649 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 650 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 651 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 652 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 653 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 654 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 655 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 656 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 657 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 658 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 659 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 660 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 661 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 662 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 663 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 664 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 665 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 666 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 667 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 668 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 669 BRAZIL: KEY MACROECONOMIC INDICATORS
  • TABLE 670 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 671 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 672 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 673 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 674 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 675 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 676 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 677 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 678 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY END USER,2022–2030 (USD MILLION)
  • TABLE 679 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 680 MEXICO: KEY MACROECONOMIC INDICATORS
  • TABLE 681 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 682 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 683 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 684 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 685 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 686 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 687 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 688 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 689 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 690 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 691 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 692 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 693 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 694 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 695 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 696 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 697 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 698 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 699 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 700 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 701 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
  • TABLE 702 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 703 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 704 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 705 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 706 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 707 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 708 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 709 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 710 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 711 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 712 GCC COUNTRIES: KEY MACROECONOMIC INDICATORS
  • TABLE 713 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 714 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 715 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 716 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 717 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 718 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 719 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 720 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 721 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 722 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 723 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 724 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 725 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 726 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 727 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 728 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 729 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 730 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 731 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 732 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 733 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 734 UAE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 735 UAE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 736 UAE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 737 UAE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 738 UAE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 739 UAE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 740 UAE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 741 UAE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 742 UAE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 743 UAE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 744 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 745 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 746 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 747 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 748 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 749 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
  • TABLE 750 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 751 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 752 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 753 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 754 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2022–APRIL 2025
  • TABLE 755 IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 756 IN VITRO DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 757 IN VITRO DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 758 IN VITRO DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 759 IN VITRO DIAGNOSTICS MARKET: END-USER FOOTPRINT
  • TABLE 760 IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 761 IN VITRO DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 762 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
  • TABLE 763 IN VITRO DIAGNOSTICS MARKET: DEALS, JANUARY 2022–APRIL 2025
  • TABLE 764 IN VITRO DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2022–APRIL 2025
  • TABLE 765 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 766 IN VITRO DIAGNOSTICS MARKET: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 767 AI-DRIVEN PRODUCTS & SERVICES PROVIDED BY KEY PLAYERS
  • TABLE 768 DANAHER: COMPANY OVERVIEW
  • TABLE 769 DANAHER: PRODUCTS/SERVICES OFFERED
  • TABLE 770 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 771 DANAHER: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 772 DANAHER: EXPANSIONS, JANUARY 2022–MARCH 2024
  • TABLE 773 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 774 F. HOFFMANN-LA ROCHE LTD: CURRENCY CONVERSION, 2022–2024
  • TABLE 775 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 776 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 777 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 778 F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2022–MARCH 2024
  • TABLE 779 ABBOTT: COMPANY OVERVIEW
  • TABLE 780 ABBOTT: PRODUCTS/SERVICES OFFERED
  • TABLE 781 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 782 ABBOTT: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 783 ABBOTT: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 784 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 785 SIEMENS HEALTHINEERS AG: CURRENCY CONVERSION, 2022–2024
  • TABLE 786 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 787 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 788 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 789 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 790 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 791 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 792 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 793 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 794 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 795 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 796 ILLUMINA, INC.: PRODUCTS OFFERED
  • TABLE 797 ILLUMINA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 798 ILLUMINA, INC.: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 799 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 800 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
  • TABLE 801 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 802 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 803 HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 804 HOLOGIC, INC.: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 805 HOLOGIC, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 806 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 807 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 808 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 809 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 810 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 811 BIOMÉRIEUX: CURRENCY CONVERSION, 2022–2024
  • TABLE 812 BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED
  • TABLE 813 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 814 BIOMÉRIEUX: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 815 BIOMÉRIEUX: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 816 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 817 SYSMEX CORPORATION: CURRENCY CONVERSION, 2022–2024
  • TABLE 818 SYSMEX CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 819 SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS,JANUARY 2022–MARCH 2025
  • TABLE 820 SYSMEX CORPORATION: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 821 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 822 REVVITY: COMPANY OVERVIEW
  • TABLE 823 REVVITY: PRODUCTS/SERVICES OFFERED
  • TABLE 824 REVVITY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 825 REVVITY: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 826 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
  • TABLE 827 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 828 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED
  • TABLE 829 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 830 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 831 BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 832 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 833 AGILENT TECHNOLOGIES, INC: PRODUCTS/SERVICES OFFERED
  • TABLE 834 AGILENT TECHNOLOGIES, INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 835 AGILENT TECHNOLOGIES, INC: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 836 AGILENT TECHNOLOGIES, INC: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
  • TABLE 837 QIAGEN: COMPANY OVERVIEW
  • TABLE 838 QIAGEN: PRODUCTS/SERVICES OFFERED
  • TABLE 839 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 840 QIAGEN: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 841 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 842 DIASORIN S.P.A.: CURRENCY CONVERSION, 2021-2023
  • TABLE 843 DIASORIN S.P.A.: PRODUCTS/SERVICES OFFERED
  • TABLE 844 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 845 DIASORIN S.P.A.: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 846 GRIFOLS, S.A.: COMPANY OVERVIEW
  • TABLE 847 GRIFOLS, S.A.: CURRENCY CONVERSION, 2022–2024
  • TABLE 848 GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED
  • TABLE 849 GRIFOLS, S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 850 GRIFOLS, S.A.: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 851 WERFEN: COMPANY OVERVIEW
  • TABLE 852 WERFEN: PRODUCTS/SERVICES OFFERED
  • TABLE 853 WERFEN: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 854 WERFEN: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 855 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 856 QUIDELORTHO CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 857 QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 858 QUIDELORTHO CORPORATION: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 859 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2024
  • TABLE 860 DEVYSER: COMPANY OVERVIEW
  • TABLE 861 BIOSYNEX SA: COMPANY OVERVIEW
  • TABLE 862 SURMODICS, INC.: COMPANY OVERVIEW
  • TABLE 863 MENARINI SILICON BIOSYSTEMS: COMPANY OVERVIEW
  • TABLE 864 SPEEDX PTY. LTD.: COMPANY OVERVIEW
  • TABLE 865 GENSPEED BIOTECH GMBH: COMPANY OVERVIEW
  • TABLE 866 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 867 CARIS LIFE SCIENCES: COMPANY OVERVIEW
  • TABLE 868 ARKRAY, INC.: COMPANY OVERVIEW
  • TABLE 869 ACCELERATE DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • TABLE 870 CELLABS: COMPANY OVERVIEW
  • TABLE 871 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
  • TABLE 872 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • TABLE 873 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
  • TABLE 874 ENZO BIOCHEM INC.: COMPANY OVERVIEW
  • TABLE 875 GENETIC SIGNATURES: COMPANY OVERVIEW
  • TABLE 876 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 877 TRIVITRON HEALTHCARE: COMPANY OVERVIEW
  • TABLE 878 MDXHEALTH: COMPANY OVERVIEW
  • TABLE 879 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 880 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
  • TABLE 881 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 882 LUYE LIFE SCIENCES GROUP: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 IN VITRO DIAGNOSTICS MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 GLOBAL IN VITRO DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS
  • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 7 TOP-DOWN APPROACH
  • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • FIGURE 9 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 10 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 11 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2025 VS. 2030 (USD MILLION)
  • FIGURE 12 IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 GEOGRAPHIC SNAPSHOT OF IN VITRO DIAGNOSTICS MARKET
  • FIGURE 16 GROWING PREVALENCE OF INFECTIOUS DISEASES AND RISING EMPHASIS ON NEED FOR EARLY DIAGNOSIS TO DRIVE MARKET
  • FIGURE 17 REAGENTS & KITS SEGMENT AND US LED NORTH AMERICAN IN VITRO DIAGNOSTICS MARKET IN 2024
  • FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 19 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 21 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 IN VITRO DIAGNOSTIC REGULATION: CRITICAL AREAS OF IMPACT
  • FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 24 IN VITRO DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 IN VITRO DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 26 IN VITRO DIAGNOSTICS MARKET: ECOSYSTEM MAPPING
  • FIGURE 27 IN VITRO DIAGNOSTICS MARKET: INVESTMENT AND FUNDING SCENARIO, 2020−2023
  • FIGURE 28 IN VITRO DIAGNOSTICS MARKET: PATENT ANALYSIS, 2014–2024
  • FIGURE 29 US: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 30 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
  • FIGURE 31 EUROPE: IN VITRO DIAGNOSTIC REGULATION (IVDR) TIMELINE
  • FIGURE 32 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN
  • FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 35 IN VITRO DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS, BY PRODUCT & SERVICE
  • FIGURE 37 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • FIGURE 38 AI USE CASES
  • FIGURE 39 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 40 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 41 IN VITRO DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD BILLION)
  • FIGURE 42 IN VITRO DIAGNOSTICS MARKET SHARE ANALYSIS, 2024
  • FIGURE 43 RANKING OF KEY PLAYERS, 2024
  • FIGURE 44 EV/EBITDA OF KEY VENDORS, 2025
  • FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025
  • FIGURE 46 IN VITRO DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 47 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 48 IN VITRO DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 49 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 50 DANAHER: COMPANY SNAPSHOT (2024)
  • FIGURE 51 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
  • FIGURE 52 ABBOTT: COMPANY SNAPSHOT (2024)
  • FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 54 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 55 ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 56 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 57 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 58 BIOMÉRIEUX: COMPANY SNAPSHOT (2024)
  • FIGURE 59 SYSMEX CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 60 REVVITY: COMPANY SNAPSHOT (2024)
  • FIGURE 61 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024)
  • FIGURE 62 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 63 QIAGEN: COMPANY SNAPSHOT (2024)
  • FIGURE 64 DIASORIN S.P.A: COMPANY SNAPSHOT (2023)
  • FIGURE 65 GRIFOLS, S.A.: COMPANY SNAPSHOT (2024)
  • FIGURE 66 WERFEN: COMPANY SNAPSHOT (2024)
  • FIGURE 67 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024)

 

This study involved the extensive use of primary and secondary sources. A comprehensive study was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions and assumptions and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. The market sizes of segments and subsegments were then estimated using data triangulation techniques and market breakdown.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), International Trade Administration (ITA), American Association for Clinical Chemistry (AACC), American Diabetes Association (ADA), Association for Molecular Pathology (AMP) and Centers for Medicare and Medicaid Services (CMS) were referred to identify and collect information for the global in vitro diagnostics market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the in vitro diagnostics market. The primary sources from the demand side include hospitals & clinics, clinical laboratories, blood banks, pharmaceutical and biotechnology companies, and academic institutes. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

In Vitro Diagnostics Market

Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2023, Tier 1= >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = < USD 1 billion.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global in vitro diagnostics market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. The global in vitro diagnostics market was split into various segments and sub-segments based on:

  • List of major players operating in the products market at the regional and/or country level.
  • Product mapping of various in vitro diagnostics manufacturers at the regional and/or country level.
  • Mapping of annual revenue generated by listed major players from in vitro diagnostics (or the nearest reported business unit/product category).
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments.
  • Summation of the market value of all segments/subsegments to arrive at the global in vitro diagnostics market.

The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Market Size Estimation (Bottom-up Approach & Top-down Approach)

In Vitro Diagnostics Market

Data Triangulation

After arriving at the overall size of the global in vitro diagnostics market through the above-mentioned methodology, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. Examining several macro variables and regional trends from demand- and supply-side players helped triangulate the extrapolated market data.

Market Definition

IVD tests are non-invasive tests performed to diagnose, monitor, screen, and assess diseases and health conditions. The term "in vitro," which refers to "in glass," signifies that test tubes or petri dishes are typically used in these tests. These tests are performed artificially on biological samples (blood, urine, and tissues). IVD has a broad scope ranging from sophisticated technologies performed in clinical laboratories to simple and easy-to-use rapid testing kits.

IVD is used to assess a person's health. This technique is used in precision medicine to determine the suitable course of treatment for particular patients and diagnose and prevent diseases and other medical disorders.

Stakeholders

  • Transfection products manufacturing companies
  • Pharmaceutical & Biopharmaceutical Companies
  • Chemical Companies
  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Research Institutes and Universities 
  • Venture Capitalists & Investors
  • Government Associations

Report Objectives

  • To define, describe, and forecast the in vitro diagnostics (IVD) market based on product & service, technology, specimen, site of testing, application, end user, and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and industry-specific challenges).
  • To assess the in vitro diagnostics market with respect to Porter’s Five Forces, regulatory landscape, the value chain, the supply chain, ecosystem analysis, patent protection, pricing assessment, key stakeholders, and buying criteria.
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
  • To analyze the opportunities in the IVD market for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of the IVD market in six primary regions (along with countries)—North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and the GCC Countries.
  • To profile the key players operating in the IVD market and comprehensively analyze their core competencies and market shares.
  • To track and analyze competitive developments such as partnerships, agreements, collaborations, acquisitions, expansions, product/technology developments, and product approvals.
  • To benchmark players within the IVD market using the Company Evaluation Quadrant framework, which analyzes market players on various parameters within categories of business strategies, market share, and product offerings.

 

Previous Versions of this Report

In Vitro Diagnostics Market by Product & Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Specimen (Blood, Saliva), Test Type, Application (Oncology, Autoimmune, CVD, Infectious Diseases) - Global Forecast to 2029

Report Code MD 3609
Published in Mar, 2024, By MarketsandMarkets™

In Vitro Diagnostics Market by Product and Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Infectious Disease), End User (Hospitals, Clinics) - Forecast to 2027

Report Code MD 3609
Published in Jan, 2023, By MarketsandMarkets™

In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2026

Report Code MD 3609
Published in Mar, 2022, By MarketsandMarkets™

In-Vitro Diagnostics Market by Product & Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2025

Report Code MD 3609
Published in Nov, 2020, By MarketsandMarkets™

In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology) - Forecast to 2023

Report Code MD 3609
Published in Mar, 2018, By MarketsandMarkets™

In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to 2021

Report Code MD 3609
Published in Dec, 2016, By MarketsandMarkets™

In Vitro Diagnostics (IVD) Market by Product (instruments, Reagents, Software, Service) by Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology) by Application (Diabetes, Cancer, Cardiology, Autoimmune Diseases) - Forecast to 2020

Report Code MD 3609
Published in Jul, 2015, By MarketsandMarkets™

In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Haematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] – Forecast To 2017

Report Code PH 2087
Published in Jul, 2013, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in In Vitro Diagnostics Market

John

Jun, 2022

Who are the key companies/players in the in-vitro diagnostics market?.

James

Jun, 2022

What are some of the notable developments in the IVD market in recent years?.

Kahlill

Jun, 2022

What are the upcoming trends of In Vitro Diagnostics Market in the world?.

DMCA.com Protection Status